# Molecular Cancer Therapeutics

## Table of Contents

### August 2018 • Volume 17 • Number 8

### Highlights of This Issue 1623

### REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1625</td>
<td>PET Imaging of Receptor Tyrosine Kinases in Cancer</td>
<td>Weijun Wei, Dalong Ni, Emily B. Ehlerding, Quan-Yong Luo, and Weibo Cai</td>
</tr>
</tbody>
</table>

### SMALL MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1648</td>
<td>TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations</td>
<td>Shinichi Hasako, Mikki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohswawa, Akihiro Hashimoto, Ryuoto Fujita, Kenji Tanaka, Takashige Okayama, Renu Wadhwa, Kazutaka Miyadera, Yoshimi Aoyagi, Kazuhiro Yonekura, and Kenichi Matsuo</td>
</tr>
<tr>
<td>1659</td>
<td>The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth</td>
<td>Yuhua Wang, Ram Naresh Pandey, Stephen Riffle, Hemabhindu Chintala, Kathryn A. Wilkenheiser-Brookamp, and Rashmi S. Hegde</td>
</tr>
<tr>
<td>1670</td>
<td>The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression</td>
<td>Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quiros Fernández, Alan Lau, Frances M. Richards, and Duncan I. Jodrell</td>
</tr>
</tbody>
</table>

### 1683 TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

Wakako Yano, Tatsushi Yokogawa, Takeshi Wakasa, Keisuke Yamamura, Akio Fujiioka, Kunihiro Yoshisue, Eiji Matsushima, Seiji Miyahara, Hiroshi Miyakoshi, Junko Taguchi, Khoa T. Chong, Yayoi Takao, Masayoshi Fukusho, and Kenichi Matsuo

### 1694 Novel Fluoroindenoisouquinoline Non-Camptothecin Topoisomerase I Inhibitors

Laetitia Marzi, Keli Agama, Junko Murai, Simone Difilippantonio, Amy James, Cody J. Peer, William D. Figg, Daniel Beck, Mohamed S.A. Elsayed, Mark Cushman, and Yves Pommier

### 1705 Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL

Michela Bardini, Luca Trentin, Francesca Rizzo, Margherita Vieri, Angela M. Savino, Patricia Garrido Castro, Grazia Fazio, Eddy H.J. Van Roon, Mark Kerstjens, Nicholas Smithers, Rab K. Piniha, Geertuy Te Kronnie, Giuseppe Basso, Ronald W. Stam, Rob Pieters, Andrea Biondi, and Gianni Cazzaniga

### 1717 The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo

Amy Wahba, Barbara H. Rath, John W. O’Neill, Kevin Camphausen, and Philip J. Tofilon

### 1727 Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Dan Zhu, Shuichan Xu, Gordafaried Deyanat-Yazdi, Sophie X. Peng, Leo A. Barnes, Rama Krishna Narla, Tam Tran, David Mikolon, Yuhong Ning, Tao Shi, Ning Jiang, Heather K. Raymon, Jennifer R. Riggs, and John F. Boylan
LARGE MOLECULE THERAPEUTICS

1739 Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

1752 Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR + and Heterogeneous Tumor Models

1761 Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer

1773 A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
Monique J. Kauke, Alison W. Tisdale, Ryan L. Kelly, Christian J. Beaun, Michael T. Hemanu, and K. Dane Wittup

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

1781 Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism

ABOUT THE COVER

A Lewis lung carcinoma xenograft tumor section was co-stained with the endothelial marker endomucin, and the proliferation marker Ki-67. These rapidly growing tumors are characterized by high endothelial and tumor cell proliferation in vascular hotspots. In this study, loss of the EYA3 tyrosine phosphatase in either host endothelial cells or tumor cells attenuated tumor growth. Loss of endothelial EYA3 reduced tumor angiogenesis while loss of tumor cell EYA3 reduced cell proliferation and survival. Key – Green: endomucin-positive endothelial cells; red: Ki-67 positive proliferating cells; blue: DAPI-stained nuclei.